^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05
Published date:
02/01/2021
Excerpt:
...1181 Korean patients with programmed death-1 ligand 1 (PD-L1)-positive...R/M-NSCLC treated with pembrolizumab or nivolumab...In multivariable analysis, concordance of TPS ≥ 50% in both PD-L1 assays and the development of immune-related adverse events (irAEs) were two significant predictors of better ORR, PFS, and OS. EGFR mutation could also predict significantly worse OS outcomes.
DOI:
10.1007/s00432-021-03527-4
Source:
Title:
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
Published date:
12/06/2023
Excerpt:
Among the 46 patients resected in the trial, a significantly higher incidence of MPR in the N/C group was observed than that in the N group among the patients with ≥ 50% PD-L1 expression (80.0% vs.18.2%, odds ratio = 14.85, 95% CI 1.50–64.91, p = 0.009).
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1038/s41392-023-01700-4
Trial ID:
Source:
Title:
Overall survival in high and very high PD-L1 expressing patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors in a real-world data setting.
Published date:
05/28/2020
Excerpt:
...positive for PD-L1 expression when treated with immune checkpoint inhibitors (ICI), including pembrolizumab (Pb) and nivolumab (Nb)....Results suggest OS benefit for real-world ICI-treated aNSCLC patients with PD-L1 TPS ≥50%, consistent with observations in clinical trials.
DOI:
10.1200/JCO.2020.38.15_suppl.e15156
Source:
Title:
A STUDY ON ANALYSIS OF CLINICAL EFFICACY FACTOR AND EXPLORING PROGNOSTIC FACTORS FOR REIMBURSEMENT POLICY AFTER IMMUNOTHERAPY BEING INTRODUCED IN SOUTH KOREA
Published date:
12/12/2019
Excerpt:
1181 patients, No. of treatment was 10.5 and 7.9 for nivolumab and pembrolizumab separately...Factors associated with response were Smoking (+), Previous RT (-), irAE(+) and PD-L1 over 50%(+), for OS were PS(+), EGFR(-), Previous RT(-) and irAE(+)…
DOI:
10.1093/annonc/mdz449
